Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis
In this study, we report the comparative result of long-term clinical prognoses for patients with no-option critical limb ischemia (CLI) caused by arteriosclerosis obliterans, who are implanted with autologous bone marrow mononuclear cells (BMMNC; n =74) or G-CSF-mobilized (M)-PBMNC ( n =111), as no...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2011-02, Vol.46 (2), p.278-284 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 284 |
|---|---|
| container_issue | 2 |
| container_start_page | 278 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 46 |
| creator | Onodera, R Teramukai, S Tanaka, S Kojima, S Horie, T Matoba, S Murohara, T Matsubara, H Fukushima, M |
| description | In this study, we report the comparative result of long-term clinical prognoses for patients with no-option critical limb ischemia (CLI) caused by arteriosclerosis obliterans, who are implanted with autologous bone marrow mononuclear cells (BMMNC;
n
=74) or G-CSF-mobilized (M)-PBMNC (
n
=111), as no information is available on how the two treatments compare in terms of long-term prognosis, such as survival or amputation. We performed pooled analysis using data from two previous cohort studies. All patients had disease of Fontaine classification III or IV. The endpoints were OS and amputation-free survival (AFS). After adjustment for history of dialysis and Fontaine classification, there was no significant difference between the two treatments with respect to OS (hazard ratio (HR)=1.49; 95% confidence interval (CI)=0.74–3.03,
P
=0.26) or AFS (HR=0.96; 95% CI=0.61–1.51,
P
=0.87). The negative prognostic factors affecting OS or AFS were the small number of CD34-positive cells collected, history of dialysis, Fontaine classification, male sex and older age. These results suggest that there was no significant difference in long-term prognosis between patients treated with BMMNC and those treated with M-PBMNC. The number of CD34-positive cells collected was an important prognostic factor for amputation and death. |
| doi_str_mv | 10.1038/bmt.2010.110 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_907149564</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A249389380</galeid><sourcerecordid>A249389380</sourcerecordid><originalsourceid>FETCH-LOGICAL-c609t-9669eb8997ada03ca126f212195fbf272fa5c9311d7269e319df8d88c782fa193</originalsourceid><addsrcrecordid>eNqF0kFv0zAUB_AIgVg3uHFGFgi4kGI7iWNzKxUbSJN2GJwjx7FbT47d2QnT9mn4qLzQQhkqQokUxf49W8_-Z9kzgucEF_xd2w9ziqc_gh9kM1LWLK8KVj3MZpgynhcFE0fZcUpXGJOyxNXj7IjishY15rPs-4fgNepljOEG9cEHPyqnZURKO5fQNx3TmNBZvrw8zfvQWmfvdIc2OtrNWkfpUOtC6A5UmhDRELUceu0HFAxy4UZH5GzfosXlxXu0CcHBUtJLd5vstsAFv8oHHXu0iWHlA4w_yR4Z6ZJ-uvueZF9PP35ZfsrPL84-LxfnuWJYDLlgTOiWC1HLTuJCSUKZoYQSUZnW0JoaWSlRENLVFGRBRGd4x7mqOUwRUZxkb7brws7Xo05D09s0tSK9DmNqBK5JKSpW_lfyCu6gZHUF8sVf8iqMERqeEAaGqwm9_BeirIQGMOV8r1bS6cZ6E4Yo1bRxs6ClKDi8GNT8gIKn071VcNPGwvi9gtd_FKy1dMM6BTcONvh0H77dQhVDSlGbZhMtxOa2IbiZcthADpsphw3kEPjzXVNj2-vuN_4VPACvdkAmJZ2J0iub9q4QuCp_nk6-dQmm_ErH_ekc3PgHhPnyvw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642190288</pqid></control><display><type>article</type><title>Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis</title><source>MEDLINE</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>Onodera, R ; Teramukai, S ; Tanaka, S ; Kojima, S ; Horie, T ; Matoba, S ; Murohara, T ; Matsubara, H ; Fukushima, M</creator><creatorcontrib>Onodera, R ; Teramukai, S ; Tanaka, S ; Kojima, S ; Horie, T ; Matoba, S ; Murohara, T ; Matsubara, H ; Fukushima, M ; BMMNC Follow-Up Study Investigators ; M-PBMNC Follow-Up Study Investigators ; BMMNC Follow-Up Study Investigators, M-PBMNC Follow-Up Study Investigators</creatorcontrib><description>In this study, we report the comparative result of long-term clinical prognoses for patients with no-option critical limb ischemia (CLI) caused by arteriosclerosis obliterans, who are implanted with autologous bone marrow mononuclear cells (BMMNC;
n
=74) or G-CSF-mobilized (M)-PBMNC (
n
=111), as no information is available on how the two treatments compare in terms of long-term prognosis, such as survival or amputation. We performed pooled analysis using data from two previous cohort studies. All patients had disease of Fontaine classification III or IV. The endpoints were OS and amputation-free survival (AFS). After adjustment for history of dialysis and Fontaine classification, there was no significant difference between the two treatments with respect to OS (hazard ratio (HR)=1.49; 95% confidence interval (CI)=0.74–3.03,
P
=0.26) or AFS (HR=0.96; 95% CI=0.61–1.51,
P
=0.87). The negative prognostic factors affecting OS or AFS were the small number of CD34-positive cells collected, history of dialysis, Fontaine classification, male sex and older age. These results suggest that there was no significant difference in long-term prognosis between patients treated with BMMNC and those treated with M-PBMNC. The number of CD34-positive cells collected was an important prognostic factor for amputation and death.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/bmt.2010.110</identifier><identifier>PMID: 20479708</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/75/593 ; 692/700/1750 ; 692/700/565/545/576/1955 ; Adult ; Aged ; Aged, 80 and over ; Amputation ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Antigens, CD34 - analysis ; Arteriosclerosis ; Arteriosclerosis Obliterans - mortality ; Arteriosclerosis Obliterans - surgery ; Autografts ; Biological and medical sciences ; Blood and lymphatic vessels ; Bone marrow ; Bone Marrow Transplantation ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Cardiology. Vascular system ; Care and treatment ; CD34 antigen ; Cell Biology ; Classification ; Confidence intervals ; Dialysis ; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous ; Female ; Granulocyte colony-stimulating factor ; Granulocyte Colony-Stimulating Factor - pharmacology ; Hematology ; Hematopoietic Stem Cell Mobilization - methods ; Hematopoietic stem cells ; Humans ; Internal Medicine ; Ischemia ; Leukocytes (mononuclear) ; Leukocytes, Mononuclear - transplantation ; Lower Extremity ; Male ; Medical prognosis ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; original-article ; Patients ; Peripheral blood mononuclear cells ; Peripheral Blood Stem Cell Transplantation ; Physiological aspects ; Prognosis ; Public Health ; Stem cell transplantation ; Stem Cells ; Survival ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>Bone marrow transplantation (Basingstoke), 2011-02, Vol.46 (2), p.278-284</ispartof><rights>Macmillan Publishers Limited 2011</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 Nature Publishing Group</rights><rights>Macmillan Publishers Limited 2011.</rights><rights>Copyright Nature Publishing Group Feb 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c609t-9669eb8997ada03ca126f212195fbf272fa5c9311d7269e319df8d88c782fa193</citedby><cites>FETCH-LOGICAL-c609t-9669eb8997ada03ca126f212195fbf272fa5c9311d7269e319df8d88c782fa193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/bmt.2010.110$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/bmt.2010.110$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23905455$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20479708$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Onodera, R</creatorcontrib><creatorcontrib>Teramukai, S</creatorcontrib><creatorcontrib>Tanaka, S</creatorcontrib><creatorcontrib>Kojima, S</creatorcontrib><creatorcontrib>Horie, T</creatorcontrib><creatorcontrib>Matoba, S</creatorcontrib><creatorcontrib>Murohara, T</creatorcontrib><creatorcontrib>Matsubara, H</creatorcontrib><creatorcontrib>Fukushima, M</creatorcontrib><creatorcontrib>BMMNC Follow-Up Study Investigators</creatorcontrib><creatorcontrib>M-PBMNC Follow-Up Study Investigators</creatorcontrib><creatorcontrib>BMMNC Follow-Up Study Investigators, M-PBMNC Follow-Up Study Investigators</creatorcontrib><title>Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>In this study, we report the comparative result of long-term clinical prognoses for patients with no-option critical limb ischemia (CLI) caused by arteriosclerosis obliterans, who are implanted with autologous bone marrow mononuclear cells (BMMNC;
n
=74) or G-CSF-mobilized (M)-PBMNC (
n
=111), as no information is available on how the two treatments compare in terms of long-term prognosis, such as survival or amputation. We performed pooled analysis using data from two previous cohort studies. All patients had disease of Fontaine classification III or IV. The endpoints were OS and amputation-free survival (AFS). After adjustment for history of dialysis and Fontaine classification, there was no significant difference between the two treatments with respect to OS (hazard ratio (HR)=1.49; 95% confidence interval (CI)=0.74–3.03,
P
=0.26) or AFS (HR=0.96; 95% CI=0.61–1.51,
P
=0.87). The negative prognostic factors affecting OS or AFS were the small number of CD34-positive cells collected, history of dialysis, Fontaine classification, male sex and older age. These results suggest that there was no significant difference in long-term prognosis between patients treated with BMMNC and those treated with M-PBMNC. The number of CD34-positive cells collected was an important prognostic factor for amputation and death.</description><subject>692/699/75/593</subject><subject>692/700/1750</subject><subject>692/700/565/545/576/1955</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Amputation</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Antigens, CD34 - analysis</subject><subject>Arteriosclerosis</subject><subject>Arteriosclerosis Obliterans - mortality</subject><subject>Arteriosclerosis Obliterans - surgery</subject><subject>Autografts</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Bone marrow</subject><subject>Bone Marrow Transplantation</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Cardiology. Vascular system</subject><subject>Care and treatment</subject><subject>CD34 antigen</subject><subject>Cell Biology</subject><subject>Classification</subject><subject>Confidence intervals</subject><subject>Dialysis</subject><subject>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</subject><subject>Female</subject><subject>Granulocyte colony-stimulating factor</subject><subject>Granulocyte Colony-Stimulating Factor - pharmacology</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Mobilization - methods</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Ischemia</subject><subject>Leukocytes (mononuclear)</subject><subject>Leukocytes, Mononuclear - transplantation</subject><subject>Lower Extremity</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>original-article</subject><subject>Patients</subject><subject>Peripheral blood mononuclear cells</subject><subject>Peripheral Blood Stem Cell Transplantation</subject><subject>Physiological aspects</subject><subject>Prognosis</subject><subject>Public Health</subject><subject>Stem cell transplantation</subject><subject>Stem Cells</subject><subject>Survival</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0kFv0zAUB_AIgVg3uHFGFgi4kGI7iWNzKxUbSJN2GJwjx7FbT47d2QnT9mn4qLzQQhkqQokUxf49W8_-Z9kzgucEF_xd2w9ziqc_gh9kM1LWLK8KVj3MZpgynhcFE0fZcUpXGJOyxNXj7IjishY15rPs-4fgNepljOEG9cEHPyqnZURKO5fQNx3TmNBZvrw8zfvQWmfvdIc2OtrNWkfpUOtC6A5UmhDRELUceu0HFAxy4UZH5GzfosXlxXu0CcHBUtJLd5vstsAFv8oHHXu0iWHlA4w_yR4Z6ZJ-uvueZF9PP35ZfsrPL84-LxfnuWJYDLlgTOiWC1HLTuJCSUKZoYQSUZnW0JoaWSlRENLVFGRBRGd4x7mqOUwRUZxkb7brws7Xo05D09s0tSK9DmNqBK5JKSpW_lfyCu6gZHUF8sVf8iqMERqeEAaGqwm9_BeirIQGMOV8r1bS6cZ6E4Yo1bRxs6ClKDi8GNT8gIKn071VcNPGwvi9gtd_FKy1dMM6BTcONvh0H77dQhVDSlGbZhMtxOa2IbiZcthADpsphw3kEPjzXVNj2-vuN_4VPACvdkAmJZ2J0iub9q4QuCp_nk6-dQmm_ErH_ekc3PgHhPnyvw</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>Onodera, R</creator><creator>Teramukai, S</creator><creator>Tanaka, S</creator><creator>Kojima, S</creator><creator>Horie, T</creator><creator>Matoba, S</creator><creator>Murohara, T</creator><creator>Matsubara, H</creator><creator>Fukushima, M</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20110201</creationdate><title>Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis</title><author>Onodera, R ; Teramukai, S ; Tanaka, S ; Kojima, S ; Horie, T ; Matoba, S ; Murohara, T ; Matsubara, H ; Fukushima, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c609t-9669eb8997ada03ca126f212195fbf272fa5c9311d7269e319df8d88c782fa193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>692/699/75/593</topic><topic>692/700/1750</topic><topic>692/700/565/545/576/1955</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Amputation</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Antigens, CD34 - analysis</topic><topic>Arteriosclerosis</topic><topic>Arteriosclerosis Obliterans - mortality</topic><topic>Arteriosclerosis Obliterans - surgery</topic><topic>Autografts</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Bone marrow</topic><topic>Bone Marrow Transplantation</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Cardiology. Vascular system</topic><topic>Care and treatment</topic><topic>CD34 antigen</topic><topic>Cell Biology</topic><topic>Classification</topic><topic>Confidence intervals</topic><topic>Dialysis</topic><topic>Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous</topic><topic>Female</topic><topic>Granulocyte colony-stimulating factor</topic><topic>Granulocyte Colony-Stimulating Factor - pharmacology</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Mobilization - methods</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Ischemia</topic><topic>Leukocytes (mononuclear)</topic><topic>Leukocytes, Mononuclear - transplantation</topic><topic>Lower Extremity</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>original-article</topic><topic>Patients</topic><topic>Peripheral blood mononuclear cells</topic><topic>Peripheral Blood Stem Cell Transplantation</topic><topic>Physiological aspects</topic><topic>Prognosis</topic><topic>Public Health</topic><topic>Stem cell transplantation</topic><topic>Stem Cells</topic><topic>Survival</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Onodera, R</creatorcontrib><creatorcontrib>Teramukai, S</creatorcontrib><creatorcontrib>Tanaka, S</creatorcontrib><creatorcontrib>Kojima, S</creatorcontrib><creatorcontrib>Horie, T</creatorcontrib><creatorcontrib>Matoba, S</creatorcontrib><creatorcontrib>Murohara, T</creatorcontrib><creatorcontrib>Matsubara, H</creatorcontrib><creatorcontrib>Fukushima, M</creatorcontrib><creatorcontrib>BMMNC Follow-Up Study Investigators</creatorcontrib><creatorcontrib>M-PBMNC Follow-Up Study Investigators</creatorcontrib><creatorcontrib>BMMNC Follow-Up Study Investigators, M-PBMNC Follow-Up Study Investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Onodera, R</au><au>Teramukai, S</au><au>Tanaka, S</au><au>Kojima, S</au><au>Horie, T</au><au>Matoba, S</au><au>Murohara, T</au><au>Matsubara, H</au><au>Fukushima, M</au><aucorp>BMMNC Follow-Up Study Investigators</aucorp><aucorp>M-PBMNC Follow-Up Study Investigators</aucorp><aucorp>BMMNC Follow-Up Study Investigators, M-PBMNC Follow-Up Study Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>46</volume><issue>2</issue><spage>278</spage><epage>284</epage><pages>278-284</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>In this study, we report the comparative result of long-term clinical prognoses for patients with no-option critical limb ischemia (CLI) caused by arteriosclerosis obliterans, who are implanted with autologous bone marrow mononuclear cells (BMMNC;
n
=74) or G-CSF-mobilized (M)-PBMNC (
n
=111), as no information is available on how the two treatments compare in terms of long-term prognosis, such as survival or amputation. We performed pooled analysis using data from two previous cohort studies. All patients had disease of Fontaine classification III or IV. The endpoints were OS and amputation-free survival (AFS). After adjustment for history of dialysis and Fontaine classification, there was no significant difference between the two treatments with respect to OS (hazard ratio (HR)=1.49; 95% confidence interval (CI)=0.74–3.03,
P
=0.26) or AFS (HR=0.96; 95% CI=0.61–1.51,
P
=0.87). The negative prognostic factors affecting OS or AFS were the small number of CD34-positive cells collected, history of dialysis, Fontaine classification, male sex and older age. These results suggest that there was no significant difference in long-term prognosis between patients treated with BMMNC and those treated with M-PBMNC. The number of CD34-positive cells collected was an important prognostic factor for amputation and death.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>20479708</pmid><doi>10.1038/bmt.2010.110</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2011-02, Vol.46 (2), p.278-284 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_907149564 |
| source | MEDLINE; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SpringerLink Journals - AutoHoldings |
| subjects | 692/699/75/593 692/700/1750 692/700/565/545/576/1955 Adult Aged Aged, 80 and over Amputation Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antigens, CD34 - analysis Arteriosclerosis Arteriosclerosis Obliterans - mortality Arteriosclerosis Obliterans - surgery Autografts Biological and medical sciences Blood and lymphatic vessels Bone marrow Bone Marrow Transplantation Bone marrow, stem cells transplantation. Graft versus host reaction Cardiology. Vascular system Care and treatment CD34 antigen Cell Biology Classification Confidence intervals Dialysis Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Female Granulocyte colony-stimulating factor Granulocyte Colony-Stimulating Factor - pharmacology Hematology Hematopoietic Stem Cell Mobilization - methods Hematopoietic stem cells Humans Internal Medicine Ischemia Leukocytes (mononuclear) Leukocytes, Mononuclear - transplantation Lower Extremity Male Medical prognosis Medical sciences Medicine Medicine & Public Health Middle Aged original-article Patients Peripheral blood mononuclear cells Peripheral Blood Stem Cell Transplantation Physiological aspects Prognosis Public Health Stem cell transplantation Stem Cells Survival Transfusions. Complications. Transfusion reactions. Cell and gene therapy |
| title | Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T18%3A03%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20marrow%20mononuclear%20cells%20versus%20G-CSF-mobilized%20peripheral%20blood%20mononuclear%20cells%20for%20treatment%20of%20lower%20limb%20ASO:%20pooled%20analysis%20for%20long-term%20prognosis&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Onodera,%20R&rft.aucorp=BMMNC%20Follow-Up%20Study%20Investigators&rft.date=2011-02-01&rft.volume=46&rft.issue=2&rft.spage=278&rft.epage=284&rft.pages=278-284&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/bmt.2010.110&rft_dat=%3Cgale_proqu%3EA249389380%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2642190288&rft_id=info:pmid/20479708&rft_galeid=A249389380&rfr_iscdi=true |